Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2020, Vol. 11 Issue (2) : 462-464     DOI: 10.14336/AD.2020.0301
Editorial |
Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
Ashok K Shetty*
Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, Texas, USA
Download: PDF(212 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (Leng et al., Aging Dis, 11:216-228, 2020). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available. Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however.

Corresponding Authors: Shetty Ashok K   
About author:

The authors equally contributed this work.

Just Accepted Date: 01 March 2020   Issue Date: 13 March 2020
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Shetty Ashok K
Cite this article:   
Shetty Ashok K. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia[J]. Aging and disease, 2020, 11(2): 462-464.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2020.0301     OR
[1] Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. (2020). Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis, 11:216-228.
[2] Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E (2020). A novel coronavirus emerging in China - key questions for impact assessment. New England Journal of Medicine, in press.
[3] Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. (2020). World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19). Int J Surg, pii: S1743-9191(20)30197-7.
[4] Chen Y, Liu Q, Guo D (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol, 92(4):418-423.
[5] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. (2020). Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395:565-574
[6] Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, in press.
[7] Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S (2020). The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv:2020.2001.2031.929042.
[8] Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Patho, 203:631-637.
[9] Fauci AS, Lane HC, Redfield RR (2020). Covid-19 - Navigating the uncharted. N Engl J Med. Feb 28.
[10] Prockop DJ, Oh JY (2012). Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther, 20:14-20.
[11] Prockop DJ (2017). The exciting prospects of new therapies with mesenchymal stromal cells. Cytotherapy, 19:1-8.
[12] Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. (2012). Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurology, 11:150-156
[13] Wilson JG, Liu KD, Zhuo NJ, Caballero L, McMillan M, Fang XH, et al. (2015). Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respiratory Medicine, 3:24-32.
[14] Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM, et al. (2016). Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematology, 3:E45-E52.
[15] Kamen DL, Nietert PJ, Wang H, Duke T, Cloud C, Robinson A, et al. (2018). CT-04 Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cells (MSCs) in patients with systemic lupus erythematosus: results of an open-label phase I study. Lupus Science & Medicine, 5:A46-A47.
[16] Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BLet al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5:54-63.
[17] Shetty AK, Upadhya R, Madhu LN, Kodali M (2019). Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer's Disease. Aging Dis, 10:470-482.
[18] Shetty AK, Kodali M, Upadhya R, Madhu LN (2018). Emerging Anti-Aging Strategies - Scientific Basis and Efficacy. Aging Dis, 9:1165-1184.
[19] Thomas R, Wang W, Su DM (2020). Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immun Ageing, 17:2.
[20] Oh SJ, Lee JK, Shin OS (2019). Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Network, 19:e37.
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd